Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesa Laboratories (MLAB) Gains from Sales and Divestitures (2018 - 2025)

Mesa Laboratories' Gains from Sales and Divestitures history spans 8 years, with the latest figure at $16.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 33.33% year-over-year to $16.0; the TTM value through Dec 2025 reached $16.0, up 33.33%, while the annual FY2025 figure was $37000.0, 32.14% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $16.0 at Mesa Laboratories, up from $4.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $37000.0 in Q1 2025 and bottomed at $4.0 in Q2 2025.
  • The 5-year median for Gains from Sales and Divestitures is $24.5 (2021), against an average of $8257.8.
  • The largest annual shift saw Gains from Sales and Divestitures crashed 99.65% in 2021 before it surged 116.67% in 2022.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $28.0 in 2021, then crashed by 64.29% to $10.0 in 2022, then skyrocketed by 100.0% to $20.0 in 2023, then tumbled by 40.0% to $12.0 in 2024, then soared by 33.33% to $16.0 in 2025.
  • Per Business Quant, the three most recent readings for MLAB's Gains from Sales and Divestitures are $16.0 (Q4 2025), $4.0 (Q3 2025), and $4.0 (Q2 2025).